148 related articles for article (PubMed ID: 20706125)
1. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
Liu X; Gelwicks S; Faries DE; Able SL
Int Clin Psychopharmacol; 2010 Nov; 25(6):315-22. PubMed ID: 20706125
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
Liu X; Tepper PG; Able SL
Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
[TBL] [Abstract][Full Text] [Related]
3. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
Vlahiotis A; Devine ST; Eichholz J; Kautzner A
J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
[TBL] [Abstract][Full Text] [Related]
6. The association between antidepressant dosage titration and medication adherence among patients with depression.
Wu CH; Farley JF; Gaynes BN
Depress Anxiety; 2012 Jun; 29(6):506-14. PubMed ID: 22553149
[TBL] [Abstract][Full Text] [Related]
7. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy.
Chen SY; Wu N; Boulanger L; Fraser KA; Zhao Y
Pain Pract; 2010; 10(6):530-9. PubMed ID: 20412505
[TBL] [Abstract][Full Text] [Related]
8. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
10. [Duloxetine receives positive recommendation by the Scientific Committee of EMEA for treatment of depression].
Krankenpfl J; 2004; 42(7-10):247. PubMed ID: 15675409
[No Abstract] [Full Text] [Related]
11. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Brecht S; Kajdasz D; Ball S; Thase ME
Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
[TBL] [Abstract][Full Text] [Related]
13. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
Pitchot W; Scantamburlo G; Ansseau M
Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
[TBL] [Abstract][Full Text] [Related]
15. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
16. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.
Cui Z; Faries DE; Gelwicks S; Novick D; Liu X
J Med Econ; 2012; 15(1):134-44. PubMed ID: 22014076
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
Lam RW; Andersen HF; Wade AG
Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
[TBL] [Abstract][Full Text] [Related]
18. [Physical complaints can overlap mental symptoms. Diffuse pain? Think about depression!].
MMW Fortschr Med; 2006 Jun; 148(23):62. PubMed ID: 16826743
[No Abstract] [Full Text] [Related]
19. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
[TBL] [Abstract][Full Text] [Related]
20. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
